Taysha Gene Therapies, Inc. TSHA Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Taysha Gene Therapies, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Taysha Gene Therapies, Inc.'s additional paid-in capital?
- Taysha Gene Therapies, Inc. (TSHA) reported additional paid-in capital of $964.67M in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s additional paid-in capital changed year-over-year?
- Taysha Gene Therapies, Inc.'s additional paid-in capital increased by 41.6% year-over-year, from $681.18M to $964.67M.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), Taysha Gene Therapies, Inc.'s additional paid-in capital has grown at a 25.1% compound annual growth rate (CAGR), from $312.43M to $958.43M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.